Neoadjuvant chemoimmunotherapy combined with surgery for patients with non-small-cell lung cancer staged as ⅢA / 中华胸心血管外科杂志
Chinese Journal of Thoracic and Cardiovascular Surgery
; (12): 516-520, 2021.
Article
em Zh
| WPRIM
| ID: wpr-912316
Biblioteca responsável:
WPRO
ABSTRACT
Objective:To explore the efficacy and safety of neoadjuvant chemoimmunotherapy combined with surgery for stage ⅢA NSCLC patients.Methods:Six patients with NSCLC who were diagnosed as ⅢA and received two cycles of neoadjuvant chemoimmunotherapy and surgery between September 2019 and January 2020 were described in this study.Results:Five of them experienced AEs during neoadjuvant therapy. All of them received surgery and achieved an MPR of 50%. No viable tumor cells were found in the tissues of one patient. One patient with a small bronchopleural fistula after lobectomy.Conclusion:Neoadjuvant chemoimmunotherapy combined with surgery for stage ⅢA NSCLC patients is safe and efficient. Long-term outcomes of neoadjuvant chemoimmunotherapy combined with surgery should be further validated.
Texto completo:
1
Base de dados:
WPRIM
Idioma:
Zh
Ano de publicação:
2021
Tipo de documento:
Article